FWIW, my sis in law was looking for something that I found on the Indiamart website.
I contacted 3 well known vendors and they all confirmed it was not actually available in India.
This one might be available, but I learned they do post things as click bait.
There is a pharma company in India producing it, but it looks to be a smaller company. I’m suspicious / leery of smaller Indian Pharma companies as their quality control tends to be worse than the major International Pharma. Another approach might be to contact a doctor through something like Push Health and try to get a US-based prescription and source.
From Gemini: Based on your request, the manufacturer and company details for Axentri 150mg Maraviroc Tablets are listed below.
Axentri is a branded generic version of Maraviroc , an entry inhibitor used in the treatment of CCR5-tropic HIV-1 infection.4 Unlike other antiretrovirals that target viral replication after cell entry, Maraviroc blocks the CCR5 receptor on the CD4 cell surface to prevent viral entry.5 As a prescription pharmaceutical, specific product pages may be restricted depending on regional compliance laws; however, the manufacturer’s corporate site provides general portfolio information.
Just a note : Rosuvastatin in some patients is associated with decreased cognition that mimics long covid. I certainly found that was the case for me. By switching to Atorvastatin (or Pitavastatin) for 7 days and then switching back to Rosuvastatin for 7 days (try it a few times) you can quickly determine if you someone who is sensitive to the effects.
Thanks for the info. I ended up ordering from Shree Signify Exim. Shipped cost is about 1/3 of that of GoodRx prices.
Been on it for three weeks at 150mg BID. Doing rehab and too early to be certain but subjectively feeling progress to be easier.
Great to hear. Keep us updated as time goes by!
More interesting news on Maraviroc that I missed earlier (July, 25):
The study utilized two dosing regimens in mice that yielded positive results:
Cellular senescence is a hallmark of organismal aging but how it drives aging in human tissues is not fully understood. Here we leverage single nucleus multiomics to profile senescence in mononucleated cells of human skeletal muscle and provide the first senescence atlas. We demonstrate the intra- and inter-populational transcriptomic and epigenomic heterogeneity and dynamics of cellular senescence. We also identify commonalities and variations in senescence-associated secretory phenotypes (SASPs) among the cells and elucidate SASP mediated cellular interactions and niche deregulation. Furthermore, we identify targetable SASPs and demonstrate the possibility of using Maraviroc as a pharmacological senotherapeutic for treating age-associated sarcopenia. Lastly, we define transcription factors that govern senescence state and SASP induction in aging muscle and elucidate the key function and mechanism of JUNB in SASP activation. Altogether, our findings demonstrate the prevalence and function of cellular senescence in skeletal muscle and identify a novel pharmacological intervention for sarcopenia.
A post was split to a new topic: Existing HIV Drug Reverses Muscle Aging by purging “Zombie Cell” Signals
Hey @NickG,
Any effects (good/bad) to report since you’ve been taking it for 2 months already? Have you done any lab tests recently(after starting Maraviroc) and what were the results? Thanks,
Walter_Brown, I assume that you’re using a 150 mg pill. If that is the case how do you manage to cut it into 10 segments?
It is available from India.
Axentri Maraviroc Tablets
"In India, Maraviroc is primarily sold under the brand name Axentri.
Brand Information
Manufacturer: Axentri is manufactured by Emcure Pharmaceuticals Ltd…
Availability: It is available in 150 mg and 300 mg tablets, typically sold in bottles of 60 tablets.’
A little about Emcure Pharmaceuticals. The lack of much export to more developed countries gives me a bit of concern about quality, as does the regulatory problems at that specific factory they produce the medicine at. I wish there were an easy, cost-effective way to have the medicine evaluated:
The following profile details the size, financial standing, and quality reputation of Emcure Pharmaceuticals Ltd. as of late 2025.
Emcure is a significant Tier-1 player in the Indian pharmaceutical market (IPM), distinct for its heavy reliance on the domestic market compared to its export-heavy peers.
| Metric | Value / Rank | Context |
|---|---|---|
| India Rank | 13th | Based on domestic sales (MAT FY24). It is the 4th largest company in its specific “covered markets” (therapeutic areas it competes in). |
| Revenue (FY24) | ₹6,658 Cr (~$800M) | Domestic sales contribute approx. 48% of total revenue, which is higher than many Indian pharma peers who rely more on US exports. |
| Revenue (TTM) | ₹8,449 Cr (~$1B) | Trailing 12-Months as of Sept 2025. Growth has accelerated recently, driven by new product launches. |
| Market Cap | ~₹27,000 Cr | Listed on NSE/BSE in July 2024. Currently valued as a mid-cap pharma stock. |
| Key Segments | #1 in Gynecology | Also holds leadership positions in HIV (Antivirals) and Iron supplements. |
Note on Growth: Emcure has outperformed the Indian Pharmaceutical Market (IPM) growth rate in domestic sales over the last 3 years (CAGR of ~10% vs industry ~8%).
Emcure’s reputation is currently in a “Recovery and Redemption” phase. Historically plagued by severe regulatory issues, the company has made significant strides in 2024–2025 to clear its compliance record.
As of December 2025, the company has successfully cleared multiple critical inspections, signaling a turnaround in manufacturing quality.
Gujarat (Kadu) Facility: Received “No Action Indicated” (NAI) status from the US FDA in December 2025 (Inspection Oct 2025). This is the highest compliance rating, meaning no objectionable conditions were found—a major “clean chit.” Sanand (Oncology) Facility: Concluded a US FDA Pre-Approval Inspection in July 2025 with Zero Observations.
Pune (API) Facility: Received 2 Observations (Form 483) in Feb 2025. However, this was later classified as VAI (Voluntary Action Indicated) in April 2025, meaning the FDA accepted their corrective plan and the facility is compliant enough to continue operations/exports.Emcure manufactures Axentri (Maraviroc) at its primary solid oral dosage facility in Pune, Maharashtra .
Based on the product packaging and regulatory filings, the specific factory details are:
Emcure Pharmaceuticals Ltd. Survey No. 255/2, Phase-I, Hinjewadi, Pune - 411 057, Maharashtra, India.
Based on the manufacturing location of Axentri (Maraviroc) at the Hinjewadi, Pune facility, here is the specific quality and regulatory status for that site.
Unlike Emcure’s newer facilities in Gujarat (which recently received a “clean” status), the Hinjewadi facility has a troubled regulatory history with the US FDA that has not yet been fully publicly resolved “close-out” as of late 2025.
1. The “Import Alert” (Ban) Status
2. Key FDA Observations (The “Red Flags”) The 2019 Warning Letter (which followed a 2015 ban) cited specific quality failures at Hinjewadi that impacted its reputation:
Summary: While Emcure as a company has cleaned up its act in 2024–2025 (clearing inspections at its Sanand and Gujarat plants), the Hinjewadi facility where Axentri is made remains the “legacy problem” site with unresolved US FDA warning letters. The quality is sufficient for domestic approval but has historically failed to meet the higher bar of US regulatory clearance.
Am I meant to be cutting it into 10 segments?! 
. I’ve been taking 150mg twice daily (or a total of 300mg per day) for the last month. Feel fine and both my neuro- physiotherapist and personal trainer have noted fresh plasticity and progress.
Been on it for three weeks at 15-mg BID.
My question was based on your statement above of 15-mg BID several posts back. Now, should the dose be 15 mg BID or 150 mg BID? I’m not sure, but it seems to me that I saw somewhere in a RapAdmin post on Maraviroc that 15 mg BID or 30 mg daily would be appropriate.
Yes, I think it was 30mg but I’d cut 150 into four pieces and do it once per day to start and then maybe go twice per day. I wouldn’t go more than 75mg daily.
Apologies, was a typo - will correct original post. Was meant to read 150mg. My mistake 
Have you ever tried LDN 3mg-4.5mg. A lot of people seem to have good results with it. I use it and it is an excellent medication for aches and pains (but never had covid so can’t speak to that). Maybe worth a shot.
@desertshores, are you considering it? At almost 81, I’m watching this space carefully. Dose, frequency, mechanism, etc.
Not just yet, I’ve already got so many meds I’m loath to start another one.
I’ve been exploring dosing approaches to try and replicate the effects from the mouse studies. The behavior of maraviroc in humans vs. mice is so different, a compounded micro dose may be needed. For now the approach I’m going with is to split 150 mg tablet into quarters (37.5 mg) and dose every 2 weeks. Here’s the analysis of that approach from Grok:
To address your question directly: yes, dosing frequency should ideally be based on the ratio of duration of inhibition to no inhibition to maintain a similar proportion of time under CCR5 inhibition, as this could better replicate the “pulsed” exposure profile in mouse studies where transient, short-lived inhibition (followed by extended troughs) led to senotherapeutic effects like reduced senescence and improved muscle/memory outcomes. However, this ratio must be adjusted for species differences in physiology (e.g., metabolism, half-life, and aging time scales) to ensure biological relevance—direct ratio matching without scaling could result in overly extended intervals that may not align with human senescence dynamics.